Hypophosphorylation of topoisomerase IIα in etoposide (VP-16)-resistant human carcinoma cell lines associated with carboxy-terminal truncation

Japanese Journal of Cancer Research

Volumn 92, Issue 7, 2001, Pages 799-805

  Matsumoto, Yoshihito ^a,b   Takano, Hiroshi ^b   Kunishio, Katsuzo ^a   Nagao, Seigo ^a   Fojo, Tito ^b  

^a KAGAWA UNIVERSITY   (Japan)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Acquired drug resistance; Etoposide; Nuclear localization; Topoisomerase II; Topoisomerase II poisons

Indexed keywords

ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II ALPHA; DNA TOPOISOMERASE II BETA; ETOPOSIDE; GLYCOPROTEIN P; ISOENZYME; TUMOR ANTIGEN; AMSACRINE; CELL EXTRACT; COMPLEMENTARY DNA; DODECYL SULFATE SODIUM; DOXORUBICIN; METHOTREXATE; POISON; POTASSIUM CHLORIDE; RIBONUCLEASE; VINCRISTINE;

ALTERNATIVE RNA SPLICING; ARTICLE; BIOSYNTHESIS; BREAST TUMOR; CARCINOMA; CELL CULTURE; DRUG RESISTANCE; ENZYMOLOGY; EXON; GENETICS; HUMAN; METABOLISM; PHOSPHORYLATION; STRUCTURE ACTIVITY RELATION; BASE PAIRING; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CARBOXY TERMINAL SEQUENCE; CELL ISOLATION; CELL NUCLEUS; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; EXPOSURE; GENE DELETION; GENE INSERTION; HUMAN CELL; PRECIPITATION; PRIORITY JOURNAL;

ALTERNATIVE SPLICING; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CARCINOMA; DNA TOPOISOMERASES, TYPE II; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; EXONS; HUMANS; ISOENZYMES; P-GLYCOPROTEIN; PHOSPHORYLATION; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0034742112     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2001.tb01164.x     Document Type: Article

References (22)

1. Cellular adaptation to drug exposure: Evolution of the drug-resistant phenotype
2. Increased phosphorylation of DNA topoisomerase II in etoposide resistant mutants of human cancer KB cells
3. A novel mutant topoisomerase IIα present in VP-16-resistant human melanoma cell lines has deletion of alanine 429
4. Function of the hydrophilic carboxyl terminus of type II DNA topoisomerase from Drosophila melanogaster
5. Serine 1524 is a major site of phosphorylation on human topoisomerase IIα protein in vivo and is a substrate for casein kinase II in vitro
6. Cell cycle phase-specific phosphorylation of human topoisomerase IIα
7. The regulation of DNA topoisomerase II by casein kinase II
8. Casein kinase II is required for transition of G0/G1, early G1, and G1/S phase of the cell cycle
9. Cloning and characterization of the 5′-flanking region of the human topoisomerase IIα gene
10. Casein kinase II phosphorylates the eukaryote-specific C-terminal domain of topoisomerase II in vitro
11. The C-terminal domain of Saccharomyces cerevisiae DNA topoisomerase II
12. Topoisomerase II forms multimer in vitro: Effects of metals, β-glycerophosphate, and phosphorylation of its C-terminal domain
13. Functional dissection of the phosphorylated termini of fission yeast DNA topoisomerase II
14. Fluorescent dye Rhodamine 6G as a molecular probe to study drug resistance of C6 rat glioma cells
15. Efficient in vitro synthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter
16. Modulation of the expression of a multidrug resistance gene (mdr-1/P-glycoprotein) by differentiating agents
17. Threonine 1342 in human topoisomerase IIα is phosphorylated throughout the cell cycle
18. Use of yeast in the study of anticancer drugs targeting DNA topoisomerases: Expression of a functional recombinant human DNA topoisomerase II alpha in yeast
19. Structural and functional analysis of the control region of the human DNA topoisomerase II alpha gene in drug-resistant cells
20. Novel actions of inhibitors of DNA topoisomerase II in drug-resistant tumor cells
21. Resistance mechanisms associated with altered intracellular distribution of anticancer agents
22. Sequence determinants of nuclear localization in the alpha and beta isoforms of human topoisomerase II